CN106420750A - Application of composition of O-(diethylamino)ethyl derivative and O-(piperazinyl)ethyl derivative of Harrisotone A in pancreatic fibrosis preventing or treating drugs - Google Patents
Application of composition of O-(diethylamino)ethyl derivative and O-(piperazinyl)ethyl derivative of Harrisotone A in pancreatic fibrosis preventing or treating drugs Download PDFInfo
- Publication number
- CN106420750A CN106420750A CN201610909049.8A CN201610909049A CN106420750A CN 106420750 A CN106420750 A CN 106420750A CN 201610909049 A CN201610909049 A CN 201610909049A CN 106420750 A CN106420750 A CN 106420750A
- Authority
- CN
- China
- Prior art keywords
- compositionss
- compound
- composition
- application
- ethyl derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of organic synthesis and medicinal chemistry and particularly relates to a composition, a preparation method and an application of the composition in preparing pancreatic fibrosis preventing or treating drugs. The invention discloses the composition and the preparation method thereof. Pharmacological experiments indicate that the composition provided by the invention has an effect of preventing or treating pancreatic fibrosis and a value in developing pancreatic fibrosis preventing or treating drugs.
Description
Technical field
The present invention relates to organic synthesiss and medicinal chemistry art are and in particular to compositionss, preparation method and its usage.
Background technology
Pancreatic gland fibrosis are the common traits of chronic pancreatitiss caused by a variety of causes, are also the tissue disease adjoint with it simultaneously
Feature of science, shows as a large amount of fibroblast proliferations and rich in the extracellular matrix connecting tissue.It is that many reasons lead to pancreas
The result of gland injury repairing, finds that pancreatic stellate cells and cytokine profiles are relevant with pancreatic gland fibrosis, pancreas fiber in the recent period
Change that current sickness rate is more and more high, be badly in need of the anti-pancreatic gland fibrosis medicine of research and development high-efficiency low-toxicity.
Existing medicine has that toxicity is big, safety is low, from natural product at present for the treatment of pancreatic gland fibrosis
Find compound or lead compound and carry out structural modification and obtain its derivant, thus obtaining the potential drug of high-efficiency low-toxicity
There is important value.
Compound I according to the present invention be one deliver within 2009 (Sheng Yin et al.,
2009.Harrisotones A–E,five novel prenylated polyketides with a rare
spirocyclic skeleton from Harrisonia perforata.Tetrahedron 65(2009)1147–1152)
Compound, we have carried out structural modification to compound I, and obtaining two new derivants is compound III and compound
IV, and be prepared for compositionss with compound III and compound IV and said composition anti-pancreatic gland fibrosis activity is evaluated,
It has anti-pancreatic gland fibrosis activity.
Content of the invention
The invention discloses new compositionss, said composition is made up of compound III and compound IV, said composition
The mass percent of middle compound III and compound IV is respectively 70% and 30%.
Compositionss disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
Pharmacodynamic experiment shows, the compositionss of the present invention have preferably anti-pancreatic gland fibrosis effect.The pharmacy of the present invention
Upper acceptable salt has same drug effect.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to concrete reality
Apply any restriction of example, but be defined in the claims.
Specific embodiment
The preparation of embodiment 1 compound Harrisotone A
Document (the Sheng Yin that the preparation method of compound Harrisotone A (I) is delivered with reference to Sheng Yin et al.
et al.,2009.Harrisotones A–E,five novel prenylated polyketides with a rare
spirocyclic skeleton from Harrisonia perforata.Tetrahedron 65(2009)1147–1152)
Method.
The synthesis of O- bromoethyl derivant (II) of embodiment 2 Harrisotone A
Compound I (472mg, 1.00mmol) is dissolved in 15mL benzene, adds tetrabutyl ammonium bromide (TBAB) in solution
(0.08g), 50% sodium hydroxide solution of glycol dibromide (3.760g, 20.00mmol) and 6mL.Mixture is Celsius 35
Degree stirring 3h.After 3h, reactant liquor is poured in frozen water, be extracted twice with dichloromethane immediately, merge organic phase solution.Then
Successively water and saturated common salt water washing 2 times are used to organic phase solution, then uses anhydrous sodium sulfate drying, last concentrating under reduced pressure removal is molten
Agent obtains product crude product.(mobile phase is product crude product silica gel column chromatography purification：Petroleum ether/acetone=100:1.5, v/v), receive
Collection brown is concentrated elution band and is flung to the yellow powder (602mg, 76%) that solvent obtains compound II.
1H NMR(500MHz,DMSO-d6) δ 5.18 (s, 2H), 4.56 (s, 2H), 3.93 (d, J=16.7Hz, 4H), 3.79
(s, 2H), 3.62 (d, J=0.9Hz, 4H), 3.15 (s, 2H), 2.48 (s, 2H), 2.41 (d, J=9.4Hz, 4H), 2.27 (s,
1H), 1.95 (s, 1H), 1.88 1.80 (m, 8H), 1.77 (d, J=15.5Hz, 7H), 1.68 (s, 1H), 1.61 (s, 1H),
1.51 (s, 1H), 1.25 (d, J=58.1Hz, 1H), 1.15 0.75 (m, 6H).13C NMR(125MHz,DMSO-d6)δ206.46
(s),198.24(s),195.44(s),190.27(s),135.27(s),120.09(s),115.02(s),84.45(s),
76.58(s),74.12(s),63.67(s),62.76(s),60.36(s),50.96(s),45.22(s),39.69(s),36.61
(s), 34.40 (s), 32.63 (s), 30.81 (d, J=8.9Hz), 28.77 (s), and 25.30 (s), 24.09 (d, J=19.2Hz),
22.77(s),18.20(s).
HRMS(ESI)m/z[M+H]+calcd for C34H50Br3O6:793.1137；found 793.1134.
The synthesis of O- (lignocaine) ethyl derivative (III) of embodiment 3 Harrisotone A
Compound II (396mg, 0.5mmol) is dissolved in the middle of 15mL acetonitrile, be added thereto to Anhydrous potassium carbonate (345mg,
2.5mmol), potassium iodide (84mg, 0.5mmol) and diethylamine (2920mg, 40mmol), mixture is heated to reflux 3h.Reaction knot
After bundle, reactant liquor is poured in frozen water, extracted 2 times with equivalent dichloromethane, merge organic faciess.Use water and saturated aqueous common salt successively
Washing merge after organic faciess, then use anhydrous sodium sulfate drying, concentrating under reduced pressure removal solvent obtain product crude product.Product crude product
Purify that (mobile phase is with silica gel column chromatography：Petroleum ether/acetone=100:1.5, v/v), collect brown and concentrate elution band, concentration is
Obtain the faint yellow solid (246.1mg, 64%) of compound III.
1H NMR (500MHz, DMSO-d6) δ 5.13 (s, 2H), 4.19 (s, 2H), 3.52 (d, J=5.3Hz, 4H), 3.21
(s, 2H), 3.04 (s, 2H), 2.85 (s, 12H), 2.64 (d, J=13.5Hz, 4H), 2.33 (s, 3H), 2.18 (s, 1H), 2.11
(s, 2H), 2.04 (s, 1H), 1.98 (s, 1H), 1.88 (s, 1H), 1.77 (d, J=5.0Hz, 7H), 1.70 (d, J=15.5Hz,
7H),1.61(s,1H),1.54(s,1H),1.44(s,1H),1.37(s,1H),1.10(s,24H).
13C NMR(125MHz,DMSO-d6)δ206.30(s),198.04(s),195.18(s),190.07(s),135.11
(s),119.89(s),114.86(s),84.15(s),76.42(s),66.70(s),62.58(s),60.18(s),59.97
(s),52.53(s),51.93(s),50.76(s),47.69(s),45.04(s),39.51(s),36.43(s),30.63(d,J
=8.9Hz), 28.61 (s), 25.10 (s), 23.93 (d, J=19.2Hz), 22.57 (s), 18.04 (s), 12.27 (s).
HRMS(ESI):m/z[M+H]+calcd for C46H80N3O6:770.6047；found:770.6044.
The synthesis of O- (piperazinyl) ethyl derivative of embodiment 4 Harrisotone A
Compound II (396mg, 0.5mmol) is dissolved in the middle of 16mL acetonitrile, be added thereto to Anhydrous potassium carbonate (345mg,
2.5mmol), potassium iodide (84mg, 0.5mmol) and Piperazine anhydrous (6892mg, 80mmol), mixture is heated to reflux 1h.Reaction
After end, reactant liquor is poured in 15mL frozen water, extracted 2 times with equivalent dichloromethane, merge organic faciess.Use water and saturation successively
Brine It merge after organic faciess, then use anhydrous sodium sulfate drying, concentrating under reduced pressure removal solvent obtain product crude product.Produce
(mobile phase is thing crude product silica gel column chromatography purification：Petroleum ether/acetone=100:1.5, v/v), collect light brown and concentrate eluting
Band obtains the Light brown solid (286.9mg, 71%) of compound IV.
1H NMR (500MHz, DMSO-d6) δ 5.14 (s, 2H), 4.21 (s, 2H), 3.53 (d, J=6.2Hz, 4H), 3.09
(s, 2H), 3.05 (s, 2H), 2.66 (s, 12H), 2.57 2.53 (m, 4H), 2.33 (d, J=15.0Hz, 15H), 2.24 (s,
1H), 2.14 (s, 2H), 2.10 (s, 1H), 2.00 (s, 1H), 1.88 (d, J=10.5Hz, 3H), 1.79 (d, J=5.0Hz,
7H), 1.71 (d, J=15.5Hz, 7H), 1.63 (s, 1H), 1.55 (s, 1H), 1.46 (s, 1H), 1.15 1.05 (m, 8H).
13C NMR(125MHz,DMSO-d6)δ206.30(s),198.04(s),195.28(s),190.07(s),135.11
(s),119.89(s),114.86(s),84.25(s),76.42(s),66.70(s),62.58(s),60.18(s),59.97
(s),54.35(s),54.16(s),53.66(s),50.78(s),45.24(s),45.06(s),39.49(s),36.45(s),
30.61 (d, J=8.9Hz), 28.61 (s), 25.10 (s), 23.93 (d, J=19.2Hz), 22.58 (s), 18.04 (s).
HRMS(ESI):m/z[M+H]+calcd for C46H77N6O6:809.5905；found:809.5901.
Embodiment 5 compositionss anti-pancreatic gland fibrosis activity
1 material
1.1 animal Wistar rats, male, body weight 180-200g.
1.2 composition dosage：0.9mg/kg.
The preparation of compositionss：Cross the powder of the 70mg compound III of 200 mesh nets after grinding and cross 200 after grinding
The powder of the 30mg compound IV of mesh net loads in tubule with cover and obtains 100mg compositionss with the mixing of turbine stirring instrument,
Obtain the solution of compositionss with the compositionss of this 100mg of water dissolution during use.
2 experimental techniques
2.1 modeling method：Wistar rat, with lumbar injection dl- ethionine 250mg/ days, continuous 2 months, may occur in which
Pancreas glandular cell reduces, the adipocellular hypertrophy of interstitial.
2.2 packets and medication
Rat model is randomly divided into model group, compositionss 0.9mg/kg group, compound III 0.9mg/kg group and compound
IV 0.9mg/kg group, separately sets blank control group.Administration group is administered after modeling starts, and is administered orally continuous 30 days；Dissect dynamic when 60 days
Thing.
2.3 Testing index
2.3.1 pancreas is taken to weigh at the end of testing.
2.3.2 pancreas hydroxyproline content measures and takes 100mg sample to be homogenized in water, and in 110 DEG C of 10N HCl, hydrolysis 20 is little
When.HCl nitrogen volatilizees, and hydrolyzate is filtered with after distilled water dissolving.Take 0.5ml liquid and 3ml citric acid phosphate buffer
(0.15M citric acid adds 0.6M disodium hydrogen phosphate) and 0.5ml are dissolved in the 1M periodic acid mixing of 9M phosphoric acid.Plus 1.75ml extracts buffering
Liquid (5 parts of toluene：5 parts of 2- methyl isophthalic acid-propanol：2 parts of 1- propanol), shake 30min, centrifugation.Tissue phase (0.6ml) and Ehrlich,
15min is placed in the mixing of s reagent.Measure trap in 565nm, make standard curve with 4- hydroxyl -1- proline and calculate concentration, content
Represented with ug/g tissue.
2.3.3 histological examination pancreatic tissues 10% formalin fix, paraffin embedding, microscopy after dyeing.To fiber
Change situation scores (0-3 divides).
3 results
The impact to rat pancreas organ coefficient for 3.1 compositionss
At the end of experiment, rat put to death, dissect, weigh in and pancreas weighs and calculates the ratio (pancreas of itself and body weight
Organ coefficient), the results are shown in Table 1.The impact to pancreas organ coefficient for the compositionss, comparing with model group has significant difference.Chemical combination
The thing III and compound IV impact to pancreas organ coefficient, compares with model group that there was no significant difference.
Table 1
* represent p<0.05, compare with model group
3.2 pancreas hydroxyproline contents measure
At the end of experiment, each group rat is carried out with pulmonary's hydroxyproline content mensure, result such as table 2.Compositionss are to hydroxyl dried meat
The impact of histidine content, comparing with model group has significant difference.The compound III and compound IV shadow to hydroxyproline content
Ring, compare with model group that there was no significant difference.
Table 2
* represent p<0.05, compare with model group
3.3 histological examination
At the end of experiment, rat put to death, dissect；The conventional embedding of specimen, fixing, HE dyeing, microscopy.
Result：Model group visible pancreas surrounding catheter extensive inflammation reaction in the 60th day；Thermophilic middle granulocyte karyolymph cellular infiltration,
Interstitial edema, bleeding and the necrosis of accidental pancreas cystencyte；Between pancreas cystencyte disappearance position and pancreas bubble, fibrosiss occur.
Compositionss can reduce inflammatory reaction and fibrosiss.Appraisal result is shown in Table 3.The impact to scoring for the compositionss, with model
Group compares significant difference.
Table 3
* represent p<0.05, compare with model group；The inflammatory cell infiltration of blank control group and Fibrosis score are all 0.
Conclusion：The present invention is by compositionss impact Fibrotic on pancreas in rat it was confirmed compositionss have anti-pancreas fibre
The effect of dimensionization.Therefore, compositionss can be used for preparing the medicine of anti-pancreatic gland fibrosis as active component.And compound III and
Compound IV no this activity is it is impossible to be used for preparing the medicine of anti-pancreatic gland fibrosis.
The preparation of embodiment 6 composition tablet involved in the present invention
Take 2 grams of compositionss, 18 grams of the customary adjuvant of tablet is prepared in addition, mix, conventional tablet presses make 100.
The preparation of embodiment 7 composition capsule involved in the present invention
Take 2 grams of compositionss, customary adjuvant such as 18 grams of the starch of capsule is prepared in addition, mix, encapsulated make 100.
Claims (6)
1. a kind of compositionss, it is characterized by said composition is made up of compound III and compound IV, compound in said composition
The mass percent of III and compound IV is respectively 70% and 30%,
2. the preparation method of compositionss as claimed in claim 1, it is characterized by：By the powder of compound III and compound IV
Powder be respectively according to mass percent and 70% and 30% be sufficiently mixed.
3. application in treatment pancreatic gland fibrosis medicine for a kind of compositionss as claimed in claim 1.
4. application in treatment pancreatic gland fibrosis medicine for the compositionss as claimed in claim 3, it is characterized by：Described compositionss
The pancreas organ coefficient caused by pancreatic gland fibrosis is reversed to decline.
5. application in treatment pancreatic gland fibrosis medicine for the compositionss as claimed in claim 3, it is characterized by：Described compositionss
The hydroxyproline content caused by pancreatic gland fibrosis is reversed to raise.
6. application in treatment pancreatic gland fibrosis medicine for the compositionss as claimed in claim 3, it is characterized by：Described compositionss
The inflammatory cell infiltration caused by pancreatic gland fibrosis is reversed to raise.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610909049.8A CN106420750A (en) | 2016-10-18 | 2016-10-18 | Application of composition of O-(diethylamino)ethyl derivative and O-(piperazinyl)ethyl derivative of Harrisotone A in pancreatic fibrosis preventing or treating drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610909049.8A CN106420750A (en) | 2016-10-18 | 2016-10-18 | Application of composition of O-(diethylamino)ethyl derivative and O-(piperazinyl)ethyl derivative of Harrisotone A in pancreatic fibrosis preventing or treating drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420750A true CN106420750A (en) | 2017-02-22 |
Family
ID=58176610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610909049.8A Withdrawn CN106420750A (en) | 2016-10-18 | 2016-10-18 | Application of composition of O-(diethylamino)ethyl derivative and O-(piperazinyl)ethyl derivative of Harrisotone A in pancreatic fibrosis preventing or treating drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420750A (en) |
-
2016
- 2016-10-18 CN CN201610909049.8A patent/CN106420750A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102675403A (en) | Synthesis of anti-hepatitis B medicine LQC-X and application thereof | |
| CN104147019B (en) | The application in preparation prevention or treatment pancreatic gland fibrosis medicine of O-(nafoxidine base) ethyl derivative of Cleistanone | |
| CN106420750A (en) | Application of composition of O-(diethylamino)ethyl derivative and O-(piperazinyl)ethyl derivative of Harrisotone A in pancreatic fibrosis preventing or treating drugs | |
| CN104825466A (en) | Applications of cleistanone O-(benzimidazolyl) ethyl derivative in preparation of drugs for preventing or treating pancreatic fibrosis | |
| CN106420719A (en) | Applications of composition of Atropurpuran derivatives in preparing medicines for preventing or treating pancreatic fibrosis | |
| CN106619620A (en) | Application of benzimidazolyl derivative and morpholino derivative composition of Atropurpuran in prevention and treatment of pancreatic fibrosis | |
| CN106822132A (en) | The piperazinyl of Atropurpuran and two hydroxyethylamine derivative compositions are used to prevent and treat pancreatic fibrosis | |
| CN106727509A (en) | Application of the composition of Harrisotone A derivatives in preventing or treating pancreatic fibrosis medicine | |
| CN105232508A (en) | Composition and application thereof to drugs for preventing or treating pancreas fibrosis | |
| CN106727522A (en) | The imidazole radicals and bischloroethylamines radical derivative composition of Atropurpuran are used to prevent and treat pancreatic fibrosis | |
| CN106727465A (en) | The derivative composition of Atropurpuran is used to prevent and treat pancreatic fibrosis | |
| CN106074529A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing preventing and treating pancreatic fibrosis medicine | |
| CN105193791A (en) | Composition and application thereof in medicine for preventing or treating pancreatic fibrosis | |
| CN106038553A (en) | Application of composition of Schiglautone A derivatives in preparation of pancreatic fibrosis control drugs | |
| CN106822111A (en) | Harrisotone A imidazole radicals and benzimidazolyl derivatives composition are used to prevent and treat pancreatic fibrosis | |
| CN106074516A (en) | The compositions of Ah draw'sing Bick acid benzimidazolyl and two hydroxyethylamine derivants prevents and treats pancreatic gland fibrosis medicine for preparation | |
| CN105878252A (en) | Application of pyrrolidyl and morpholino derivative composition of virosaine A in drugs for preventing or treating pancreatic fibrosis | |
| CN104739846A (en) | Application of O-(1H-tetrazole) ethyl derivative of cleistanone to preparing drug for preventing or treating pancreatic fibrosis | |
| CN105853427A (en) | Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs for preventing or treating pancreatic fibrosis | |
| CN106176733A (en) | The application in prevention or treatment pancreatic gland fibrosis medicine of the derivative composition of Schiglautone A | |
| CN106074480A (en) | The compositions of the derivant of Artalbic acid prevents and treats pancreatic gland fibrosis medicine for preparation | |
| CN105343089A (en) | Composition and application thereof in drugs for preventing or treating pancreatic fibrosis | |
| CN105287555A (en) | Composition and application thereof to medicines for preventing or treating pancreatic fibrosis | |
| CN105998003A (en) | Application of composition of Salviskinone A benzimidazolyl and di(2-methylmercapto ethyl)amido derivatives in drugs for preventing or treating pancreas fibrosis | |
| CN105343081A (en) | Composition and application of composition in medicines for preventing or treating pancreas fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170222 |
|
| WW01 | Invention patent application withdrawn after publication |